Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Pricing Avoids The Limelight During State Of The Union Address

Executive Summary

President Trump did not offer any new proposals on drug pricing during an evening featuring campaign theatrics on both sides. 

You may also be interested in...



Trump Administration Signals Deference To Congress On Drug Pricing Policy

In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.

Medicaid Demo’s Formularies Include Protections For HIV, Behavioral Health Drugs

Healthy Adult Opportunity initiative (don’t call it block grants) adopts some, but not all, of Medicare Part D’s protected classes, allowing states to exclude some drugs from coverage in the expansion Medicaid population to drive additional savings.

US Drug Pricing Legislation Efforts Headed Toward Spring Renewal? A Look Ahead

Senate legislation taking aim at price increases faces uphill climb, but sponsors are hoping President Trump will mobilize more support among congressional Republicans in the coming year.

Related Content

Topics

UsernamePublicRestriction

Register

PS141629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel